Linsitinib (OSI-906)

For research use only. Not for use in humans.

目录号:S1091

Linsitinib (OSI-906) Chemical Structure

CAS No. 867160-71-2

Linsitinib (OSI-906)是一种选择性IGF-1R抑制剂,在无细胞试验中IC50为35 nM;对InsR抑制作用适中,IC50为75 nM,对Abl,ALK,BTK,EGFR, FGFR1/2,PKA等没有抑制活性。Phase 3。

规格 价格 库存 购买数量  
RMB 1393.48 现货
RMB 2226.24 现货
RMB 5899.91 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Linsitinib (OSI-906)发表文献115篇:

产品安全说明书

IGF-1R抑制剂选择性比较

生物活性

产品描述 Linsitinib (OSI-906)是一种选择性IGF-1R抑制剂,在无细胞试验中IC50为35 nM;对InsR抑制作用适中,IC50为75 nM,对Abl,ALK,BTK,EGFR, FGFR1/2,PKA等没有抑制活性。Phase 3。
靶点
IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
35 nM 75 nM 75 nM
体外研究

OSI-906 抑制IGF-IR自磷酸化和下游信号蛋白AKT, ERK1/2和S6激酶的激活,IC50为0.028到 0.13 μM。OSI-906通过与C-螺旋相互作用而使靶点蛋白形成中间结构形态。OSI-906作用于肝脏微粒体,具有良好的代谢稳定性。OSI-906浓度为1μM时,完全抑制IR 和IGF-IR磷酸化。OSI-906抑制一些肿瘤细胞系增殖,包括非小细胞肺癌和结肠直肠癌(CRC)肿瘤细胞系,EC50为0.021到 0.810 μM。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk NUfnZWF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHKTWM2OD1yLkCyPFA3KM7:TR?= NGO0OppUSU6JRWK=
KS-1 M4HSVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEO2fWRKSzVyPUCuNFM5OzVizszN NF3HSlZUSU6JRWK=
TE-11 M4r0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzGTWM2OD1yLkC3PFIzKM7:TR?= M3Lrd3NCVkeHUh?=
EW-1 NVjxcFBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLjTWM2OD1yLkC4OVg2KM7:TR?= MnPsV2FPT0WU
HMV-II M2O2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWSzO5lHUUN3ME2wMlA5QDR4IN88US=> M2jQS3NCVkeHUh?=
COLO-205 NWDQbG5FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnSWGF3UUN3ME2wMlExPDV2IN88US=> NIrBWWRUSU6JRWK=
ES1 MmHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jtWGlEPTB;MD6xNFY6PiEQvF2= NHPtdIRUSU6JRWK=
GDM-1 M3f6dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTrWGxKSzVyPUCuNVM3PzJizszN NGfYNndUSU6JRWK=
ML-2 NETjfYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTwTXVKSzVyPUCuNVU5QTZizszN MmTnV2FPT0WU
Saos-2 M4TYNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDzTWM2OD1yLkG2OVI3KM7:TR?= NVfxNXk2W0GQR1XS
NCI-H1355 NV3hT2U{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfRNlRRUUN3ME2wMlE5OTN3IN88US=> MmjhV2FPT0WU
G-401 M4jsWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHRTWM2OD1yLkG4NlMh|ryP Mly0V2FPT0WU
EW-16 NFXqUG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXORXVKSzVyPUCuNVg4PzdizszN NH7FenhUSU6JRWK=
EW-7 M2jFe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;NSWlEPTB;MD6xPFg5OSEQvF2= M{X0dHNCVkeHUh?=
NCI-H727 NXq5O2p1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTBwMUm3PVQh|ryP MXLTRW5ITVJ?
LCLC-97TM1 M{P4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HESmlEPTB;MD6yNFk2PSEQvF2= M1LvZ3NCVkeHUh?=
NCI-H650 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofqTWM2OD1yLkKxN|g1KM7:TR?= NH7RTXRUSU6JRWK=
NCI-H2122 MlnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnqxTWM2OD1yLkKzNlk6KM7:TR?= M{LTWHNCVkeHUh?=
SK-N-DZ M{LsTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLBd|ZCUUN3ME2wMlI{Pjl6IN88US=> NYni[IdXW0GQR1XS
HT-29 NUTS[5p6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LlXGlEPTB;MD6yOFI1QCEQvF2= NYK3WWFjW0GQR1XS
LB771-HNC MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\1[G5KSzVyPUCuNlU6OTVizszN NY[1[JlWW0GQR1XS
HT-144 NEPORmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\EU|g{UUN3ME2wMlI3OTlzIN88US=> NIrZUItUSU6JRWK=
LAN-6 M4fHVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwMk[zOFgh|ryP MVjTRW5ITVJ?
EW-18 NH7WT21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;tWZlKSzVyPUCuNlcxODFizszN MVfTRW5ITVJ?
LS-1034 M4ftUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3iwSmlEPTB;MD6yO|E{OiEQvF2= NHryTGdUSU6JRWK=
EW-11 NEGyTFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPFNI9KSzVyPUCuNlg1OzJizszN M1P3OXNCVkeHUh?=
SNU-C1 MoXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPRTWM2OD1yLkK5N|E{KM7:TR?= NIrCcGpUSU6JRWK=
RS4-11 MknWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TCVWlEPTB;MD6zN|c2QCEQvF2= NX3VN3ozW0GQR1XS
ES4 MnLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\SeGlEPTB;MD60NVA{QCEQvF2= MVnTRW5ITVJ?
COLO-320-HSR NUnNVXZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfyZ2pKSzVyPUCuOFE{PjhizszN M{XWfHNCVkeHUh?=
NB10 NYnJOIZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXmZ2ZKSzVyPUCuOFU1OzdizszN NV;lWYM1W0GQR1XS
BFTC-905 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELSd49KSzVyPUCuOFY4PThizszN MojHV2FPT0WU
A375 NEfpTYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TzbWlEPTB;MD60O|YyPyEQvF2= M3;RcnNCVkeHUh?=
SJRH30 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PEb2lEPTB;MD61NFgzOiEQvF2= M2TNOnNCVkeHUh?=
NOS-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjFTWM2OD1yLkWyNlY4KM7:TR?= NF\qU4NUSU6JRWK=
SIG-M5 NGTabolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPndFE2UUN3ME2wMlU{PTV5IN88US=> M2LwVHNCVkeHUh?=
DOK MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfUWXBKSzVyPUCuOVU3KM7:TR?= MmDZV2FPT0WU
NB69 M4HlOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4D5[WlEPTB;MD61PFI2PyEQvF2= MUPTRW5ITVJ?
SK-NEP-1 MnfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4X6[WlEPTB;MD62NFI{PiEQvF2= NGjwTI9USU6JRWK=
SK-MM-2 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXyTWM2OD1yLk[1OFkyKM7:TR?= M1[5THNCVkeHUh?=
NCI-H358 MlO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwNkewPFIh|ryP MXPTRW5ITVJ?
RH-1 NV\NO5RrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTBwN{S4OVkh|ryP MoLQV2FPT0WU
NH-12 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXiOYlKSzVyPUCuO|YxPDZizszN MoXrV2FPT0WU
TE-12 NIXle|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUX6eoo2UUN3ME2wMlc3PDh4IN88US=> NYnFXXlNW0GQR1XS
COLO-668 NUW0N3EyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XLTWlEPTB;MD64OFY3PiEQvF2= NXvE[lNCW0GQR1XS
PANC-08-13 NFSzOFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTFTWM2OD1yLki2N|c4KM7:TR?= NWj6V5p{W0GQR1XS
HCC2998 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzCWWtKSzVyPUCuPFgzPjNizszN NXzFPHlRW0GQR1XS
ABC-1 M1XIZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTBwOUCzOVIh|ryP M4XVdnNCVkeHUh?=
ES6 MkXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3ywcGlEPTB;MD65NVA3PiEQvF2= M{LqNHNCVkeHUh?=
SNU-387 NGjucWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M365PGlEPTB;MD65PVM6OyEQvF2= NFvSd4xUSU6JRWK=
CMK NXjMOoVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTBwOUm5Nlkh|ryP M{T2RXNCVkeHUh?=
SJSA-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVP1OmhNUUN3ME2xMlA{PjV|IN88US=> NV;ybZZIW0GQR1XS
SIMA NICw[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPxTWM2OD1zLkC2PFI2KM7:TR?= NIPTcGFUSU6JRWK=
ES3 NWnqT3duT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\6TWM2OD1zLkGyNlk4KM7:TR?= MknUV2FPT0WU
IGROV-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTFwMUW0OFQh|ryP NX3Me2hCW0GQR1XS
MEL-JUSO NYn5fYdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfsZldoUUN3ME2xMlE2PzV7IN88US=> NUe2OoF3W0GQR1XS
T84 NEnIWJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDz[mRHUUN3ME2xMlIxQTF2IN88US=> NGi1PJFUSU6JRWK=
CAL-85-1 NYHEbWFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHObJBjUUN3ME2xMlI{OTN6IN88US=> M4jObnNCVkeHUh?=
RD NIHHN|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTFwMk[0OVUh|ryP MkPtV2FPT0WU
TE-8 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIS2[lhKSzVyPUGuN|E1PjJizszN MoLIV2FPT0WU
L-363 NYDVNmdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHz4V3RKSzVyPUGuN|QzODhizszN NVrucFZMW0GQR1XS
EKVX NWHYO|ZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULlXVNVUUN3ME2xMlM1PTZ6IN88US=> MmKwV2FPT0WU
SK-MEL-3 NV;4VXc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfGNHdZUUN3ME2xMlQ5PTV4IN88US=> NHfzfGlUSU6JRWK=
TGBC24TKB Mke4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rWcGlEPTB;MT61NFE6OyEQvF2= NFfoSJdUSU6JRWK=
NCI-H1770 NVvwU5JHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LRPWlEPTB;MT61NVEyOyEQvF2= MmHIV2FPT0WU
HuH-7 NIrK[I1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TOS2lEPTB;MT62NFA6QCEQvF2= NFrFZlNUSU6JRWK=
HL-60 M1;zfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4j0cWlEPTB;MT62OlkzQCEQvF2= M4Pmb3NCVkeHUh?=
TE-1 NGTxeINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnq[G8xUUN3ME2xMlcxQTR3IN88US=> M1zGSnNCVkeHUh?=
LC-2-ad NUDObVNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\jO29jUUN3ME2xMlc{QDh5IN88US=> MWjTRW5ITVJ?
LB647-SCLC M4nVO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTFwN{[1PFMh|ryP NY\Md4VlW0GQR1XS
NCI-H2171 NH7iVVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3H6PWlEPTB;MT63O|cyPiEQvF2= NGi4TYtUSU6JRWK=
SK-PN-DW M2X1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Dq[WlEPTB;MT65NVI6QCEQvF2= M3S5RXNCVkeHUh?=
MC-IXC NU\hdY5HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYD5ZXVDUUN3ME2xMlk5QThizszN M1\Y[XNCVkeHUh?=
LS-513 Ml3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTJwMEWzNFUh|ryP NEnuXIVUSU6JRWK=
EW-3 NIj0XnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DFc2lEPTB;Mj6wPVg1PCEQvF2= MlrwV2FPT0WU
OPM-2 NX:4VHh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PEe2lEPTB;Mj6xNFIh|ryP M4DlRXNCVkeHUh?=
LP-1 NXXv[pVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTJwMkW4NFch|ryP NWfLclBiW0GQR1XS
LU-134-A NYixO49PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\pTWM2OD1{LkK3O{DPxE1? NEDMbZBUSU6JRWK=
CP66-MEL NF;LRZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknaTWM2OD1{LkK5NFE1KM7:TR?= Mk\UV2FPT0WU
HCC1143 MmL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7iTZJKSzVyPUKuOFU{PjhizszN M2XiVHNCVkeHUh?=
LOXIMVI M2\OR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XTNGlEPTB;Mj62NFIyKM7:TR?= M4LJfXNCVkeHUh?=
TE-10 M2n4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnFTWM2OD1{LkewPFM5KM7:TR?= M32wd3NCVkeHUh?=
NCI-H1882 M2eyXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWK0bIZJUUN3ME2yMlc2OjJ5IN88US=> NELBSGdUSU6JRWK=
CHP-126 MkeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTJwN{[zNVch|ryP NFLNNYVUSU6JRWK=
NCI-H1623 MleyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDTdpZKUUN3ME2yMlkzODJ2IN88US=> M2PBfXNCVkeHUh?=
GB-1 NGLocpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13RNGlEPTB;Mj65N|QxPCEQvF2= NWDJRYlyW0GQR1XS
RCC10RGB NFrCRlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7GfY1rUUN3ME2yMlk2OjhzIN88US=> MlvXV2FPT0WU
NCI-H2141 M2iwNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHO[W9KSzVyPUKuPVY5QTZizszN NHjneYVUSU6JRWK=
GI-ME-N M3W2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV73SJVJUUN3ME2zMlAxPTZ3IN88US=> MV\TRW5ITVJ?
NCI-H526 M3\TeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\1TWM2OD1|LkC0NFg2KM7:TR?= NGm3dHRUSU6JRWK=
NCI-H747 NI\4cmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTHTWM2OD1|LkC0PVkzKM7:TR?= M3TYb3NCVkeHUh?=
SNU-423 M{nXNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPMTWM2OD1|LkKwN|E{KM7:TR?= MX7TRW5ITVJ?
A427 NIHVNY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XobmlEPTB;Mz6yOVY6QSEQvF2= Mlm5V2FPT0WU
CAL-12T NInm[5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVexUnJ6UUN3ME2zMlQxPzF|IN88US=> M1zRUnNCVkeHUh?=
LU-99A M{WxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH32Z4xKSzVyPUOuOFcyODVizszN MYDTRW5ITVJ?
MS-1 NEPBOnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTuTWM2OD1|LkWzOFI6KM7:TR?= MmLIV2FPT0WU
SK-LU-1 M2fLd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDCWGEzUUN3ME2zMlc3Ojl3IN88US=> NHzMfnFUSU6JRWK=
SW837 NHe4[ZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFO2RWpKSzVyPUOuO|Y{OzNizszN M2XNNHNCVkeHUh?=
ES8 NYHDUZF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTNwOEO4O|ch|ryP NV31UZA2W0GQR1XS
MZ2-MEL M{DUXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33wcGlEPTB;Mz65NlA5PiEQvF2= MXHTRW5ITVJ?
TGW NXr0O4F[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFi5UGJKSzVyPUSuNFE{OTFizszN M1O5S3NCVkeHUh?=
GP5d M3vtemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUT4PJpWUUN3ME20MlA2OzZ{IN88US=> M1\jd3NCVkeHUh?=
BB49-HNC MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTRwMUWyNVMh|ryP M2G4T3NCVkeHUh?=
NB13 NYDtfZBHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH6xbJlKSzVyPUSuNlY5QDdizszN MkTvV2FPT0WU
NTERA-S-cl-D1 NYXHfHhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTRwMki2NVUh|ryP M1nucHNCVkeHUh?=
NCI-H1648 M1HOVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fYd2lEPTB;ND6yPVgyQSEQvF2= NWLvPFlPW0GQR1XS
LCLC-103H NEHrV49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTOdYRbUUN3ME20MlMzOTl3IN88US=> M1q4cHNCVkeHUh?=
LS-411N NV[wWINXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHWVJBMUUN3ME20MlQ1QDh3IN88US=> MkDFV2FPT0WU
NCI-H1092 NX7HO4RZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXOUZBKSzVyPUSuOFU3QDdizszN NVTXXIdWW0GQR1XS
PANC-10-05 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrHc2JKSzVyPUSuOlk5PCEQvF2= NXOzbmRzW0GQR1XS
DK-MG NIq5fHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXhTWM2OD12LkiwPVM{KM7:TR?= M4LERXNCVkeHUh?=
OVCAR-5 MkXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIq4SFNKSzVyPUSuPFEzOjZizszN MYrTRW5ITVJ?
CAL-39 M{XkXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLoTWM2OD12Lki3Olch|ryP NI\zOJBUSU6JRWK=
TE-441-T MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTRwOUC1N|ch|ryP MV\TRW5ITVJ?
MOLT-16 NHf1c29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37ZfmlEPTB;ND65OVI2OyEQvF2= NHvFbHlUSU6JRWK=
MCF7 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\oOFltUUN3ME21MlE1PTF5IN88US=> M1jiXHNCVkeHUh?=
CAPAN-1 NIPtRYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLiTWM2OD13LkK1O|A4KM7:TR?= MniwV2FPT0WU
PSN1 MlnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTVwMkeyN|Uh|ryP MmHHV2FPT0WU
NCI-H292 NFz0VXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17tZmlEPTB;NT6zNFA1PCEQvF2= MoTqV2FPT0WU
CPC-N NEjkbG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jDTWlEPTB;NT6zPVQyQSEQvF2= MnfRV2FPT0WU
DoTc2-4510 M1LUXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nRWGlEPTB;NT60OVM4OSEQvF2= Mny0V2FPT0WU
LB1047-RCC NFf4SmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTa[YhnUUN3ME21MlU2QTN|IN88US=> NFu0TmNUSU6JRWK=
MHH-ES-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\mTWM2OD13LkW5PVA4KM7:TR?= MlHOV2FPT0WU
NMC-G1 NUDEd45LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnPO3JKSzVyPUWuO|AzOjdizszN MoiyV2FPT0WU
SW1710 MoW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTVwN{S3OVEh|ryP NEnISIpUSU6JRWK=
YAPC M4rTeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTVwN{[yNFEh|ryP NViyNHRkW0GQR1XS
22RV1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHOfVVIUUN3ME21MlgxODF7IN88US=> M{fhU3NCVkeHUh?=
COLO-679 NEeybWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLs[WlXUUN3ME21Mlg5QTR6IN88US=> MWfTRW5ITVJ?
TCCSUP Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTVwOUOyOVkh|ryP M2S4SnNCVkeHUh?=
C2BBe1 M1n6dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TI[WlEPTB;NT65N|k4KM7:TR?= NFP1bIRUSU6JRWK=
TE-15 NH;kS3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPMO4hKSzVyPU[uNFY3ODVizszN M4DicnNCVkeHUh?=
SCLC-21H M3rzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTZwMUC4OFMh|ryP NVTKVHRUW0GQR1XS
EoL-1-cell NGD6[5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTuPVVnUUN3ME22MlE3PTZ|IN88US=> NHf1bYFUSU6JRWK=
NKM-1 M1XyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jieGlEPTB;Nj6xOlcyKM7:TR?= NWnjO|RoW0GQR1XS
NCI-H1304 MnS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEK4WFRKSzVyPU[uNlc1OjhizszN NI\OOGtUSU6JRWK=
NB6 M1LCcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTZwMkm2NlIh|ryP MUPTRW5ITVJ?
NALM-6 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrGTWM2OD14LkOzNlMh|ryP NEDSSW5USU6JRWK=
NCI-H522 M2\JN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHNeGpKSzVyPU[uN|M{ODZizszN NFTkfG5USU6JRWK=
MV-4-11 MkG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTZwM{ewO|kh|ryP NIG5PFVUSU6JRWK=
LB2241-RCC M2Xzb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1j1d2lEPTB;Nj6zPFY3PyEQvF2= MW\TRW5ITVJ?
NCI-H1417 MmO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPJXINsUUN3ME22MlQxQDR5IN88US=> M3HlbXNCVkeHUh?=
HT-1197 NWnDOmhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrzSXRKSzVyPU[uOVcyOjJizszN M4OyUHNCVkeHUh?=
P30-OHK M{LUZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTUcnFpUUN3ME22MlYzPzdizszN NEC0PFdUSU6JRWK=
ALL-PO M1mwWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTZwN{G5NVYh|ryP NUjaSVlSW0GQR1XS
OVCAR-4 NES3TW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYK3XW9JUUN3ME22Mlc2PDB3IN88US=> NEG1RnhUSU6JRWK=
HCC2157 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nnbmlEPTB;Nj63O|Q4PSEQvF2= M2\sdnNCVkeHUh?=
NCI-H838 NFH5dY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTZwOU[0PUDPxE1? NXqxepI{W0GQR1XS
NCI-H1299 MlLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvCO|VrUUN3ME22Mlk4ODlizszN NV[zcYRuW0GQR1XS
SW954 NUiyblJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTdwMkCwOlgh|ryP NIr2TmdUSU6JRWK=
NCI-H441 MoLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnP0TWM2OD15LkO0NFY2KM7:TR?= M1PudnNCVkeHUh?=
SK-MEL-2 NIX2WFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LoeGlEPTB;Nz60PFM4OyEQvF2= NH;5[o9USU6JRWK=
KARPAS-45 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTdwNkW5Nlkh|ryP MYDTRW5ITVJ?
CAL-54 MkfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zremlEPTB;Nz64Nlk4PyEQvF2= Mm\nV2FPT0WU
KYSE-180 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPNN2pKSzVyPUeuPFg6PDFizszN NFPITYdUSU6JRWK=
NCI-H187 NGrpOYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfnTWM2OD15Lkm1PVQ4KM7:TR?= NHHMWGJUSU6JRWK=
RT-112 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jzb2lEPTB;OD6wPVY4PyEQvF2= MmnXV2FPT0WU
NCI-H1437 NXfJUJQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTQTWM2OD16LkC5O|k2KM7:TR?= MYnTRW5ITVJ?
SNU-449 MlruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRThwMkiyO|Ih|ryP NVTLd3JmW0GQR1XS
HCC1187 NYrFdYp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUWyO|FbUUN3ME24MlI6OzlzIN88US=> MmXlV2FPT0WU
NCI-H2030 M1jxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPWd5RKSzVyPUiuN|c4OTRizszN NE[4WGJUSU6JRWK=
HuO-3N1 NV[3bGVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTGTWM2OD16LkO3PFQ1KM7:TR?= MlzaV2FPT0WU
COLO-792 NW[0R|Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3UfpdKSzVyPUiuOFE2OjdizszN NWLXNVVoW0GQR1XS
MIA-PaCa-2 MlPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPUTWM2OD16Lki1OVA5KM7:TR?= M2TUS3NCVkeHUh?=
SK-N-FI MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTlwMESyOUDPxE1? M{jCcXNCVkeHUh?=
MMAC-SF MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTlwMEm3OVEh|ryP NInYTlZUSU6JRWK=
NCI-H28 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HGWGlEPTB;OT6xNFQ3QSEQvF2= MojwV2FPT0WU
ETK-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn33TWM2OD17LkK5PVc1KM7:TR?= MkfmV2FPT0WU
NCI-H1993 M1\PNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;jTWM2OD17LkS0NlYyKM7:TR?= Mk\YV2FPT0WU
no-11 NXTvW|RQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfVRYN6UUN3ME25MlQ4OTJizszN NVvXSJE1W0GQR1XS
ChaGo-K-1 MlfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEP5WYhKSzVyPUmuOVE2QDNizszN MXPTRW5ITVJ?
NCCIT NIC0OIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjMO4lKSzVyPUmuOVMyPjlizszN NGrIVohUSU6JRWK=
SAS NYTIeoVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTFyLkK0PEDPxE1? M1viWHNCVkeHUh?=
A673 MkX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrY[|d4UUN3ME2xNE4{PzB2IN88US=> M{TJWHNCVkeHUh?=
NCI-H1522 NY\jZ3VKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTMflBKSzVyPUGwMlM4ODdizszN MoLlV2FPT0WU
NCI-H810 NYfiNm9QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjyTWM2OD1zMD6zPVA4KM7:TR?= MnO5V2FPT0WU
IST-MES1 NY\INIlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nSZWlEPTB;MUCuOFU3PCEQvF2= MXHTRW5ITVJ?
GR-ST NYTPe|k5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjyXXdwUUN3ME2xNE42ODJ2IN88US=> M1P2XnNCVkeHUh?=
SUP-T1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2OxNGlEPTB;MUCuO|MyPyEQvF2= MlWxV2FPT0WU
NB5 MnvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYf5UXpkUUN3ME2xNE46ODJ{IN88US=> NVq5cFlwW0GQR1XS
MZ1-PC NF3VXY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7PV|VKSzVyPUGwMlk2PzFizszN M3nEcnNCVkeHUh?=
SK-CO-1 NET1PINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;6WmlEPTB;MUCuPVk{OSEQvF2= M2DQbHNCVkeHUh?=
Capan-2 MkTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\WS2lEPTB;MUGuN|E6QCEQvF2= NWfaSZJrW0GQR1XS
697 MoSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTFzLk[3OVch|ryP NG\VfHlUSU6JRWK=
REH MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvnTWM2OD1zMT63OFUyKM7:TR?= MoDvV2FPT0WU
GI-1 NWe2eFlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXL3cGlxUUN3ME2xNU45PjF3IN88US=> Mn;mV2FPT0WU
BB65-RCC MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDUZXJtUUN3ME2xNk4xQTF4IN88US=> NGHlNWZUSU6JRWK=
NCI-H1651 NHrYV|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTF{LkK0O|gh|ryP MlzYV2FPT0WU
NCI-H1618 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX:1fGdtUUN3ME2xNk4{QTd4IN88US=> MXTTRW5ITVJ?
NCI-H2081 NFHlfXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTIU45KSzVyPUGyMlYyPDFizszN MWjTRW5ITVJ?
GCIY NF7iWJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\1PHFtUUN3ME2xNk44OjF|IN88US=> M{nUO3NCVkeHUh?=
NY MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXwTWM2OD1zMz6wOlQ{KM7:TR?= MWTTRW5ITVJ?
PANC-03-27 NEC1UWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTF|LkC4NFch|ryP MX3TRW5ITVJ?
BHY NFLlN3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLzdWJMUUN3ME2xN{4zOTJzIN88US=> Mn:4V2FPT0WU
SK-OV-3 M3zF[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3kTWM2OD1zMz6zO|Y{KM7:TR?= NYn6V2xPW0GQR1XS
5637 M4fKN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPyPJRKSzVyPUGzMlc4PTlizszN NXz0dHpDW0GQR1XS
LC-1F M3yzc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljYTWM2OD1zND6wN|U3KM7:TR?= NX;NR3hkW0GQR1XS
SNB75 M3;zUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHTTWM2OD1zND6wN|g{KM7:TR?= NH:zO3hUSU6JRWK=
CHP-212 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LVeGlEPTB;MUSuNFQ3PCEQvF2= M4XqcnNCVkeHUh?=
HT-1376 NHP5RmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\ud2lEPTB;MUSuNVEzPiEQvF2= M1vVXHNCVkeHUh?=
MONO-MAC-6 NIi0dpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTF2LkG1NFIh|ryP NVzObo1JW0GQR1XS
CA46 MoLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjlOJhQUUN3ME2xOE4yQDJ5IN88US=> NVL6[XRyW0GQR1XS
SCC-15 NWn4[HUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLaTWM2OD1zND61OVg{KM7:TR?= NV[yWI03W0GQR1XS
ATN-1 NILL[odIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrWfHBKSzVyPUG0MlY3OjdizszN MlrzV2FPT0WU
NCI-H2405 NVLhS45LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XBfmlEPTB;MUSuPFE2PyEQvF2= NGHKeINUSU6JRWK=
NCI-H716 M3zzXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33vcWlEPTB;MUSuPFQ6OyEQvF2= MljIV2FPT0WU
SW620 NVL1fWMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3y5e2lEPTB;MUSuPVAyPCEQvF2= M4ntOnNCVkeHUh?=
NCI-H226 MmX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\HVmlEPTB;MUSuPVA5PSEQvF2= M33GT3NCVkeHUh?=
SW962 M4XlXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEC1[4JKSzVyPUG0Mlk1OzJizszN MkfHV2FPT0WU
KYSE-150 NIjlfIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF6xV2JKSzVyPUG0Mlk2PSEQvF2= NIK5Z|BUSU6JRWK=
OCUB-M NYXnVoNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3zTIRVUUN3ME2xOE46QDh|IN88US=> MX\TRW5ITVJ?
ES7 Mm\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTF3LkC5PFQh|ryP MmLwV2FPT0WU
SW1463 MluyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnYXm46UUN3ME2xOU41OjJ|IN88US=> MX7TRW5ITVJ?
CAKI-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LFfmlEPTB;MUWuOVM1PiEQvF2= NEXySIhUSU6JRWK=
MKN28 MkPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTF3LkW0O|kh|ryP MoXuV2FPT0WU
SW13 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHQXVhKSzVyPUG1MlYyQCEQvF2= M4rtTXNCVkeHUh?=
A3-KAW Mmj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTF3Lkm2PVch|ryP NX7HdWVJW0GQR1XS
LU-65 M3\HZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTF3Lkm3Olgh|ryP MX;TRW5ITVJ?
Calu-1 NGLrcJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvqe5lZUUN3ME2xOk4xOzZ6IN88US=> NH\aVFdUSU6JRWK=
ST486 MkjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mle1TWM2OD1zNj6wOFMyKM7:TR?= NGixbY5USU6JRWK=
BB30-HNC MnrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmr1TWM2OD1zNj6xNlQ3KM7:TR?= MX3TRW5ITVJ?
EGI-1 M{LFcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHUTWM2OD1zNj60OFYh|ryP M{G2W3NCVkeHUh?=
SH-4 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTF4LkS3N|Eh|ryP MWHTRW5ITVJ?
MN-60 M{LF[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTF5LkKyPVch|ryP M3jSVnNCVkeHUh?=
MPP-89 MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofjTWM2OD1zNz6yOFU6KM7:TR?= NVO0WVBjW0GQR1XS
A2780 NGD5fJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfsTWM2OD1zNz60NVM6KM7:TR?= NHvFcW5USU6JRWK=
Daoy NI\KRZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Hkc2lEPTB;MUeuOFY6PSEQvF2= Mn\lV2FPT0WU
NCI-H2126 M{XyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nDN2lEPTB;MUeuOFc4OSEQvF2= M2jFW3NCVkeHUh?=
NCI-H1563 NUK3N5NQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkOyTWM2OD1zNz60PVE4KM7:TR?= M1jQOHNCVkeHUh?=
8-MG-BA M3z0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTF5Lk[2OFgh|ryP MXHTRW5ITVJ?
786-0 NGTEfFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjPNVRKSzVyPUG3Mlg{PTNizszN MojGV2FPT0WU
AM-38 M1rKbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LvZWlEPTB;MUeuPVMxPiEQvF2= M3XzS3NCVkeHUh?=
COLO-824 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFK0R5JKSzVyPUG4MlQ1OzZizszN NXvzTHVXW0GQR1XS
SK-MEL-30 M3K1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHy3V5lKSzVyPUG4MlUxQDJizszN NF3xPGdUSU6JRWK=
CESS MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlf5TWM2OD1zOD63OlA6KM7:TR?= MlizV2FPT0WU
BL-70 NF3NN|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPITWM2OD1zOD64NVU3KM7:TR?= MVnTRW5ITVJ?
NCI-H2170 MlnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTF6LkmxO|kh|ryP M2[3UXNCVkeHUh?=
HT-3 MnzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH36bnRKSzVyPUG4Mlk5OyEQvF2= NXvKOVZrW0GQR1XS
BOKU NGjNcpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDkTWM2OD1zOT6wN|gyKM7:TR?= M4jPcnNCVkeHUh?=
HPAF-II M1jROGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3YTWM2OD1zOT6zNFE2KM7:TR?= M17kU3NCVkeHUh?=
KGN MlHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrMS5NKSzVyPUG5MlQ4PjVizszN MoSwV2FPT0WU
MC-CAR M1XKT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTF7Lk[zNVMh|ryP M1fLUXNCVkeHUh?=
BHT-101 M4jLemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{CxOGlEPTB;MUmuO|c4KM7:TR?= M2WxSXNCVkeHUh?=
SW1783 MnzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrHTWM2OD1zOT63PFA3KM7:TR?= Mki2V2FPT0WU
KP-N-YN NFvkd2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfaN|lKSzVyPUKwMlAzPjJizszN NHLGXGNUSU6JRWK=
LU-165 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTkTWM2OD1{MD61OVcyKM7:TR?= NWXHTIR3W0GQR1XS
GOTO Mlu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTJyLk[0OVEh|ryP NHLWUnVUSU6JRWK=
EFM-19 NV34XpltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDxOod6UUN3ME2yNU4xPzF4IN88US=> MU\TRW5ITVJ?
CTV-1 MoHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LsWmlEPTB;MkGuNVA2PCEQvF2= MYnTRW5ITVJ?
HEL MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1G5cmlEPTB;MkGuOFIyPiEQvF2= M2Wyd3NCVkeHUh?=
SNU-C2B NUG1NnpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2f0cWlEPTB;MkGuOFI3KM7:TR?= MlnQV2FPT0WU
ECC4 NUW1T2ZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjaTWM2OD1{MT63NFch|ryP Ml7yV2FPT0WU
NEC8 MlLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfhTWM2OD1{MT64N|Y5KM7:TR?= NGHhXW1USU6JRWK=
KMOE-2 Mn65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTJzLki5NlEh|ryP NXHiRnp4W0GQR1XS
NCI-H524 M1HLdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTJ{LkC4NFgh|ryP NIrnfpZUSU6JRWK=
WSU-NHL MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HYcGlEPTB;MkKuNVU4PyEQvF2= M1LwZ3NCVkeHUh?=
SF126 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTzPGE3UUN3ME2yNk4zPDZ7IN88US=> MVfTRW5ITVJ?
HOP-92 NYX3bWRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTsSG5qUUN3ME2yNk4{OTZ5IN88US=> MXXTRW5ITVJ?
CTB-1 M3jwe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYH6Um9TUUN3ME2yNk41Pjd5IN88US=> MVrTRW5ITVJ?
KYSE-270 NYDxdFBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvkTWM2OD1{Mj65N|U4KM7:TR?= M4fsOHNCVkeHUh?=
SK-MEL-24 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHITWM2OD1{Mz6xPFch|ryP NYjhXGh{W0GQR1XS
Calu-3 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnqzTWM2OD1{Mz6yNVI5KM7:TR?= MWfTRW5ITVJ?
GAMG NH3pV2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\uTWM2OD1{Mz6yN|Y4KM7:TR?= M330cnNCVkeHUh?=
SW1573 NU[ydFVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTJ|Lke0NVUh|ryP MVXTRW5ITVJ?
MHH-NB-11 NWT4V49UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2r0OWlEPTB;MkSuNFE6PCEQvF2= NYjX[WdWW0GQR1XS
TK10 NH;HN|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37nUWlEPTB;MkSuOVAyOyEQvF2= NX7JOXFWW0GQR1XS
LB373-MEL-D M3Kz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTJ2Lk[wOlQh|ryP MmOyV2FPT0WU
KALS-1 M2f5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDiTWM2OD1{ND63N|I4KM7:TR?= MYLTRW5ITVJ?
HUTU-80 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHSd3pKSzVyPUK1MlgxOzJizszN M1vEbXNCVkeHUh?=
HuP-T3 M1zCNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETRXVVKSzVyPUK2MlE3PzRizszN NXfxW2poW0GQR1XS
OE19 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml61TWM2OD1{Nj6yNVU{KM7:TR?= NYDz[4kxW0GQR1XS
J82 MlPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTJ4LkK0O|Eh|ryP MkKwV2FPT0WU
DU-4475 M2HlcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zwc2lEPTB;Mk[uN|gyQSEQvF2= NYPQTnBQW0GQR1XS
DMS-53 NY\HNm1nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTJ4LkWxN|gh|ryP Mn3hV2FPT0WU
COLO-741 NVzBfYpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LocmlEPTB;Mk[uPFM1PCEQvF2= NYfDTJRYW0GQR1XS
SW48 M{HPdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojITWM2OD1{Nj64PFIh|ryP MYTTRW5ITVJ?
IGR-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[wTWM2OD1{Nj65N|M1KM7:TR?= M{LJTXNCVkeHUh?=
639-V MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTJ5LkCyOFUh|ryP M{\mVHNCVkeHUh?=
LK-2 NFHaUFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHX2O|RKSzVyPUK3MlQyPDFizszN MUjTRW5ITVJ?
NCI-H2347 MoH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnjN|VUUUN3ME2yO{46Pjl7IN88US=> M{nRPXNCVkeHUh?=
NCI-H2228 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm[3TWM2OD1{OD6wPVA2KM7:TR?= Mo\zV2FPT0WU
LS-123 Mkf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVT0VFhCUUN3ME2yPE4yOjZ{IN88US=> NYjCW5R7W0GQR1XS
U031 NF3CfIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HCfWlEPTB;MkiuNlUzKM7:TR?= M2TNWnNCVkeHUh?=
NCI-H1792 M4DHTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrBTWM2OD1{OD60O|IyKM7:TR?= MXTTRW5ITVJ?
NCI-H2087 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPLTWM2OD1{OD63OVUzKM7:TR?= MoO5V2FPT0WU
NCI-H2342 NF3p[|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTJ7LkWyNFgh|ryP MVrTRW5ITVJ?
SW626 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHrTWM2OD1{OT63OVYh|ryP NGO1WGxUSU6JRWK=
LB2518-MEL NEHKV4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzUTWM2OD1{OT64NVUh|ryP MoWzV2FPT0WU
RXF393 M1njUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;0fGlEPTB;M{CuNFk2OiEQvF2= NVfVZWE1W0GQR1XS
LC4-1 M1rFSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7WTWM2OD1|MD6zNFkzKM7:TR?= NIPneWhUSU6JRWK=
NCI-H1694 M4rOVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnNc4V1UUN3ME2zNE43PjJ2IN88US=> M4rjfXNCVkeHUh?=
K5 Mom3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfNVYZKSzVyPUOwMlk4ODJizszN MlXhV2FPT0WU
HDLM-2 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jIWmlEPTB;M{CuPVczPSEQvF2= NXjuTnpoW0GQR1XS
BCPAP NWn0W3pVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlG3TWM2OD1|MT64N|c6KM7:TR?= MoP2V2FPT0WU
BC-3 MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nxPWlEPTB;M{KuNVQxOyEQvF2= NID5cXdUSU6JRWK=
LB996-RCC NFf0PW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkP5TWM2OD1|Mj6yN|U5KM7:TR?= MkHSV2FPT0WU
NCI-H2009 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlm0TWM2OD1|Mj60PVgyKM7:TR?= MmjJV2FPT0WU
HTC-C3 MlLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjSTWM2OD1|Mz63OVE6KM7:TR?= MXXTRW5ITVJ?
LAMA-84 NF7mTHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmK0TWM2OD1|ND60OFA4KM7:TR?= MX3TRW5ITVJ?
CCRF-CEM MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvjTWM2OD1|ND61O|E2KM7:TR?= NFjhcWdUSU6JRWK=
AN3-CA MmH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXYfVZtUUN3ME2zOU4xPTZ6IN88US=> MYjTRW5ITVJ?
NCI-H1734 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\Ub3BYUUN3ME2zOU4zPTZzIN88US=> M{P4ZnNCVkeHUh?=
Ca-Ski NFPY[WNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTN3LkSxNFEh|ryP MWnTRW5ITVJ?
U-266 NFHn[VBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvFTWM2OD1|NT62NVE1KM7:TR?= MmLSV2FPT0WU
SBC-5 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTIV2U6UUN3ME2zOU44PzhzIN88US=> MX3TRW5ITVJ?
GT3TKB Mo\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DWNWlEPTB;M{euNVE2KM7:TR?= MnW0V2FPT0WU
MDA-MB-175-VII MlfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDoTWM2OD1|Nz6yNlQ5KM7:TR?= NIrQNGVUSU6JRWK=
PFSK-1 NXLTbGp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4SybGlEPTB;M{euNlQ{PSEQvF2= NFzlSIRUSU6JRWK=
IMR-5 NXO2W3hpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;ZR20zUUN3ME2zO{4zPDh5IN88US=> NEfobIxUSU6JRWK=
Daudi MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLSSZNkUUN3ME2zO{4{PTl5IN88US=> MVnTRW5ITVJ?
A498 NH7tRmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DpNGlEPTB;M{euO|IyQCEQvF2= NXTN[GFbW0GQR1XS
SCC-4 M37XSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLNeWJ3UUN3ME2zO{44QDR|IN88US=> M2HoPHNCVkeHUh?=
COLO-680N NIjhc29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jDdmlEPTB;M{iuNlg5PSEQvF2= M3XneXNCVkeHUh?=
SK-MES-1 M{izTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfRSZJoUUN3ME2zPE4{OjF3IN88US=> NIm1VJFUSU6JRWK=
SR MmrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPFTWM2OD1|OD61OFk2KM7:TR?= NGLjclBUSU6JRWK=
LNCaP-Clone-FGC MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTN6LkW2N|ch|ryP MYjTRW5ITVJ?
SK-HEP-1 M360R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nDO2lEPTB;M{iuO|gzOiEQvF2= NWC2VoJKW0GQR1XS
BPH-1 M1njOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnzTWM2OD1|OD64N|I6KM7:TR?= NYnqXYU5W0GQR1XS
NCI-H1755 NUHpT2JmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrkTWM2OD1|OT61PFE4KM7:TR?= MWTTRW5ITVJ?
LXF-289 NYS3NVN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTN7LkiwPFQh|ryP MX\TRW5ITVJ?
SW1088 NGnHSGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHSwUWJKSzVyPUSwMlIyODdizszN Mo\DV2FPT0WU
MOLT-4 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7xfnJ3UUN3ME20NE4zQTBzIN88US=> MVXTRW5ITVJ?
AsPC-1 M4PYTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7ld4lKSzVyPUSwMlQ2QDNizszN NUXGN5ZpW0GQR1XS
HOP-62 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTRyLk[1Olgh|ryP M37Qb3NCVkeHUh?=
A172 M4DaNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3ITWM2OD12MD64OVEyKM7:TR?= MVzTRW5ITVJ?
SN12C NWrkcXBNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrnVo1bUUN3ME20NE46Ozh3IN88US=> M3O2PXNCVkeHUh?=
MDA-MB-231 MmThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTRyLkm4PVgh|ryP NXXFWmxjW0GQR1XS
RPMI-2650 MlrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DmcmlEPTB;NEGuNVU6OyEQvF2= MoTrV2FPT0WU
KYSE-140 NEL0Z3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\WN2lEPTB;NEGuPFEzOyEQvF2= NVW4cYZmW0GQR1XS
KINGS-1 NETIW|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3PTWM2OD12Mj60Olk4KM7:TR?= MUTTRW5ITVJ?
HSC-3 MnzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\tTWM2OD12Mj62OlYyKM7:TR?= M2PUZnNCVkeHUh?=
PC-14 MkT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTR|LkG4PFIh|ryP NFLqR5NUSU6JRWK=
COR-L105 MknjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\UV4RXUUN3ME20N{43PTB{IN88US=> M{DZWHNCVkeHUh?=
BE-13 NX6zeWpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\mOnpVUUN3ME20OE4zOzdzIN88US=> NFvybFRUSU6JRWK=
NCI-H661 MoDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXS0PFdMUUN3ME20OE4zQTV6IN88US=> MkO3V2FPT0WU
IST-MEL1 M1X2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTR2LkO1PVkh|ryP MVXTRW5ITVJ?
HCC1806 NVHhW4xNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\aSWlEPTB;NESuOVg4OyEQvF2= MWTTRW5ITVJ?
COLO-800 NF2wSm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33xXWlEPTB;NESuPFQ2OyEQvF2= NEm3bW9USU6JRWK=
IST-SL2 NX3QNFJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjIOJByUUN3ME20OU4yOjR5IN88US=> NU\yUY9zW0GQR1XS
8305C NHTGSW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;DWmlEPTB;NEWuN|A6KM7:TR?= NWnXbZFNW0GQR1XS
UACC-62 NVG0XWxqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rvW2lEPTB;NE[uNlg4PSEQvF2= NWWyT2hoW0GQR1XS
COR-L23 M2XLVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILj[mNKSzVyPUS3MlE6QSEQvF2= NHO1TolUSU6JRWK=
EFE-184 NVjGOYhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rtbmlEPTB;NEeuN|g5KM7:TR?= MljJV2FPT0WU
DMS-114 Mn3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTSPIV{UUN3ME20O{41OTR7IN88US=> M4P1UnNCVkeHUh?=
KYSE-520 NIXZZnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPIPVV3UUN3ME20PE42OzF3IN88US=> NXf3ZVJVW0GQR1XS
SNG-M NXjpPWE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PJUWlEPTB;NEmuOFM1KM7:TR?= NET1Z2lUSU6JRWK=
A2058 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTWTWM2OD12OT60PFg2KM7:TR?= NYLUZo51W0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-EGFR / EGFR / p-IGF1R / IGF1R / p-IRS1 / IRS1 / p-ERK / ERK / p-AKT / AKT; 

PubMed: 26052929     


Effects of linsitinib on EGFR and IGF1R Signaling Pathways. H1975, AR1, AR2 and AR3 cells were treated with control DMSO or linsitinib (2 and 5 μM) for 24 hours. Cell lysates were subjected to Western blot analysis. IGF1R-IRS-1-AKT phosphorylation was effectively inhibited by linsitinib in afatinib resistance cells whereas IRS-1-AKT phosphorylation was up-regulated by linsitinib in H1975 parental cells.

p-IGF1R / IGF1R / p-mTOR / mTOR ; 

PubMed: 28440057     


Linsitinib inhibits the activation of ERK and PI3K pathways. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, the phosphorylation of insulin‐like growth factor‐1 receptor (IGF‐1R), ERK1/2, and AKT/mTOR pathways were analyzed in TE‐13, TE‐1, and KYSE‐510 cell lines by western blot.

cleaved caspase-3 / cleaved PARP; 

PubMed: 28440057     


Reduced apoptosis in Linsitinib-resistant esophageal squamous cell carcinoma cells. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, cleaved PARP and activated Caspase‐3 were examined in TE-13, TE-1, and KYSE-510 cells by western blot. Tubulin was used as a loading control.

pSrc(Y416) / Src; 

PubMed: 26515601     


A549, H226Br, and H1975 cells were treated with 1 or 2 μM linsitinib (diluted in RPMI 1640 medium containing 10% FBS) for 12 or 24 h. Before harvest, cells were further stimulated with 10% FBS for 20 min. Cells were lysed with modified RIPA buffer and the protein expression was determined by Western blot analysis.

p-STAT3(Y705) / STAT3 ; 

PubMed: 26041671     


H226B and H460 cells were subject to daily treatment with linsitinib (1 μM) for 1-5 days.

pS6 / S6; 

PubMed: 21257723     


Western blot of NCI-H292 cells following 30 minutes of exposure to OSI-906 shows target inhibition of pIGF-1R and pIR at all doses as well as inhibition of downstream targets pAKT and pS6.

26052929 28440057 26515601 26041671 21257723
Immunofluorescence
FoxO1; 

PubMed: 27535223     


After starvation, control or βIRKO β-cell lines were treated with insulin (10 nm) in combination with high glucose (450 mg/dL), in the presence or absence of PI3K inhibitor LY294002, insulin receptor, and IGF1 receptor dual inhibitor OSI-906, Akt inhibitor MK2206, or MEK1/2 inhibitor U0126 for 30 min.  A, representative pictures of β-cells immunostained for FoxO1 (red) and DAPI (blue). The scale bar indicates 20 μm.

27535223
Growth inhibition assay
Cell viability; 

PubMed: 26136493     


InsR/IGF1R dual inhibitors, OSI-906 and BMS-754807, dose-dependently inhibited T4105 viability.

26136493
体内研究 OSI-906 作用于IGF-IR驱动的移植瘤鼠模型,抑制肿瘤生长,按 75 mg / kg剂量处理,导致100% TGI和 55% 衰退,按25 mg/kg剂量处理,导致 60% TGI,没有衰退。OSI-906处理犬,大鼠和小鼠,诱导不同的消除半衰期,消除半衰期分别为1.18 小时, 2.64小时 和2.14小时。OSI-906按不同剂量单独处理给药雌性Sprague-Dawley 大鼠和雌性CD-1小鼠,每天一次,Vmax值与OSI-906 剂量不成比例。OSI-906 按 25 mg/kg剂量处理12天,提高血糖值。OSI-906按75 mg/kg 剂量单独处理IGF-IR-驱动的人全长人类IGF-IR (LISN)移植鼠模型,在4 和24小时间最大程度抑制IGF-IR磷酸化(80%),血浆药物浓度为26.6-4.77 μM。[1] OSI-906 按60 mg/kg剂量单独作用于NCI-H292 移植鼠,处理2,4,24小时,抑制糖吸收。OSI-906 作用于NCI-H292移植鼠模型,抑制肿瘤生长。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

蛋白激酶生化实验:

通过以ELISA为基础的检测法(IGF-IR, IR, EGFR 和 KDR)或使用100 µM ATP的放射检测法进行蛋白激酶检测实验。在内部ELISA检测实验中,使用聚 (Glu:Tyr)作为底物,结合到96孔实验板表面,使用辣根过氧化物酶标记的自磷酸化抗体测定磷酸化。使用ABTS作为过氧化物酶底物,通过在405/490 nm处测量吸光度而测定结合的抗体。所有实验使用纯化的重组激酶催化域。在昆虫细胞中,人类IGF-IR或EGFR的重组酶表达作为NH2-末端谷胱甘肽S-转移酶融合蛋白,且在内部纯化。通过抑制百分数对log10药品浓度的S型剂量-反应曲线测定IC50值。进行内部实验需重复进行实验,除非另有说明,取三次测量的最小值。
细胞实验:[1]
- 合并
  • Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 和Hepa-1, RKO 3T3/hulGF-IR, H292 细胞
  • Concentrations: 0.02-0.8 μM
  • Incubation Time: 3天
  • Method: 为了测定细胞增殖,细胞接种在含FCS 10%的合适培养基上,在不同浓度OSI-906存在时,温育3天。通过细胞内ATP含量的荧光量化,使用CellTiterGlo测定抑制细胞生长的情况。数据作为衡量最大增殖的一部分,通过在不同浓度 OSI-906存在时的细胞密度除以对照组(只用DMSO处理)细胞密度。
    (Only for Reference)
动物实验:[1]
- 合并
  • Animal Models: IGF-IR驱动的全长人类IGF-IR (LISN) 移植小鼠模型
  • Dosages: 25 mg/kg和75 mg/kg
  • Administration: 口服处理,每天一次,持续14天
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 84 mg/mL (199.29 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5%DMSO+40%PEG300+5%Tween80+50%ddH2O
6.25mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 421.49
化学式

C26H23N5O

CAS号 867160-71-2
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02546544 Completed Drug: Linsitinib Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01672736 Terminated Drug: ASP7487 Velcade Dexamethasone Multiple Myeloma University Health Network Toronto|Multiple Myeloma Research Consortium|Astellas Pharma Inc September 2012 Phase 1|Phase 2
NCT01529684 Completed Drug: radio-labeled OSI-906|Drug: OSI-906 Advanced Solid Tumors|Pharmacokinetics of 14C-OSI-906 Astellas Pharma Global Development Inc.|Astellas Pharma Inc March 19 2012 Phase 1
NCT01221077 Completed Drug: OSI-906|Drug: Erlotinib|Drug: Placebo NSCLC|Non Small Cell Lung Cancer Astellas Pharma Inc April 8 2011 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

  • 回答:

    OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

相关IGF-1R产品

Tags: 购买Linsitinib (OSI-906) | Linsitinib (OSI-906)供应商 | 采购Linsitinib (OSI-906) | Linsitinib (OSI-906)价格 | Linsitinib (OSI-906)生产 | 订购Linsitinib (OSI-906) | Linsitinib (OSI-906)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID